Biogen Withdraws Alzheimer’s Drug Application in Europe

Published on April 22, 2022

In a disappointing turn of events, Biogen Inc has decided to withdraw its marketing authorization application for the Alzheimer’s drug aducanumab in Europe. Despite Biogen’s efforts to prove the drug’s benefits, the regulator remains unconvinced. This setback showcases the challenging nature of developing effective treatments for Alzheimer’s disease, which is often referred to as the brain’s version of a complicated puzzle. Just like assembling a complex jigsaw puzzle, scientists are meticulously piecing together the intricate mechanisms of this devastating condition. While the withdrawal of aducanumab in Europe is a setback, it opens up opportunities to explore other treatment options and accelerate research efforts in this field. It is crucial that we continue to invest in innovative approaches to unravel the mysteries of Alzheimer’s and develop breakthrough therapies that can provide hope for patients and their families.

Biogen Inc said on Friday it has decided to withdraw the marketing authorization application for its troubled Alzheimer’s drug, aducanumab, in Europe after it failed to convince the regulator of the drug’s benefits.The drugmaker said the move follows its interactions with…

Read Full Article (External Site)

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes:

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>